Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Safety of Alfuzosin (SL77.0499-10) in BPH
NCT00347061Phase 3Completed
- Sponsor
- Sanofi
- Start
- May 2006
- Primary completion
- Oct 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of alfuzosin in benign prostatic hyperplasia (BPH), sponsored by Sanofi. Primary endpoint: Safety of SL77.0499-10 at 1 year. Started May 2006; status: completed.
02
Drugs
alfuzosin
03
Conditions
benign prostatic hyperplasia (BPH)
Beyond the preview
Go deeper on NCT00347061.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00347061.